BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 109.50 -1.58 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $111.08 | 52 Week High | $18.39 | |||
| Open | $111.92 | 52 Week Low | $6.96 | |||
| Day High | $111.92 | P/E | N/A | |||
| Day Low | $109.27 | EPS | $-0.58 | |||
| Volume | 854,071 | |||||
